Key Highlights

  • The company updated fiscal 2027 Revenue guidance to $1,280 million to $1,290 million.
  • Adjusted diluted EPS guidance is $4.48 to $4.55.
  • Results for the second quarter and first half of fiscal 2027 were released on November 5, 2026.
  • The company operates a portfolio of over-the-counter healthcare and household brands.

Prestige Consumer Healthcare Inc. (NYSE:PBH), a marketer of over-the-counter healthcare and household brands, reported results for the second quarter and first half of fiscal 2027 ended September 2026. The company updated its fiscal 2027 outlook to revenue of $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55.

Sector Context

Consumer healthcare companies sell brands such as pain relievers, cold remedies, eye care and household cleaners through mass retailers, drug chains and e-commerce. Demand is consistent in many categories because products are used regularly, but results can depend on retailer shelf space, promotional activity and the private-label products that compete with branded goods.

Companies in the group often grow through acquisitions of established brands, which adds revenue but requires integration and Debt management. Investors therefore watch organic performance alongside reported guidance.

Updated Fiscal 2027 Guidance

The updated revenue range of $1,280 million to $1,290 million and adjusted diluted EPS range of $4.48 to $4.55 form the central outlook in the release. The highlights do not state the prior ranges, so readers should compare them with the company's earlier guidance to measure the change.

Because the guidance is expressed in both revenue and per-share terms, it shows management's expectation for both top-line growth and profit conversion across the fiscal year.

Second-Quarter Results

The company reported second-quarter and first-half fiscal 2027 results on November 5, 2026. The highlights in this release focus on the updated outlook, and readers will need the full tables to see quarterly revenue, gross Margin and cash flow.

Guidance updates after the first half typically reflect performance to date and expectations for the holiday selling season, which is an important period for consumer health products.

The midpoint of the updated revenue range is about $1,285 million, and the midpoint of the adjusted EPS range is about $4.52. The width of the revenue range is roughly 0.8% of its midpoint, and the EPS range is roughly 1.6%, which shows a narrow band of expectations for the fiscal year.

Because the release gives both revenue and EPS ranges, readers can judge whether margins are expected to expand or hold as sales grow. Consumer healthcare brands often depend on retail shelf space, so the holiday period is a key test for the company's sell-through.

Key Risks

Private-label competition and retailer pricing pressure could reduce branded sales. Acquisitions and debt levels add Financial Risk if integration or cash generation falls short. Changes in regulation for over-the-counter products could also affect the portfolio.

What to Watch Ahead

Investors will look for whether the company achieves revenue within the $1,280 million to $1,290 million range and whether adjusted EPS lands within $4.48 to $4.55. Holiday season sell-through and any change in the Brand portfolio will be the key reference points.